Read More

Akoya Biosciences Announces Preliminary Financial Results For Q4 And FY23 And Provides 2024 Outlook; Sees Q4 Revenue $25.5M-$26.5M Vs $26.28M Est.; FY23 Revenue $95.6M-$96.6M Vs $96.6M Est.; Expects FY24 Revenue To Grow 20%+

Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023

AKYA

Read More

IDEAYA Biosciences Says Balance Sheet Of $511.1M Of Cash, Cash Equivalents And Marketable Securities As Of September 30, 2023, And $134.7M Est. Net Proceeds From Follow-On Financing And $10M Receivable From GSK, Is Anticipated To Fund Operations Into 2…

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare

IDYA

Read More

RxSight, Inc. Announces Preliminary Unaudited Q4 And FY23 Financial And Operational Results And 2024 Guidance; Sees Q4 Revenue $28.6M Vs $25.76M Est.; Sees FY23 Revenue $89.1M Vs $86.34M Est.; Sees FY24 Revenue $128M-$135M Vs $121.48M Est.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational

RXST

Read More

Ultragenyx Reports Preliminary 2023 Revenue; Guidance For 2024 Revenue And Cash Usage; Pipeline Updates And 2024 Milestones; Sees FY23 Revenue $430-$435M Vs $435.9M Est.; Sees FY24 Revenue $500M-$530M Vs $523.86M Est.; Year-End 2023 Cash Balance Of ~$7…

Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million2024 expected Total Revenue guidance

RARE